Siyi Jiang

Changsha, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

MALT1 in cerebrospinal fluid: a prognostic biomarker and potential therapeutic target in Alzheimer's disease.

MALT1 in cerebrospinal fluid: a prognostic biomarker and potential therapeutic target in Alzheimer's disease.

Journal: Frontiers in neurology
Published: October 26, 2025

Hepatocyte SLCO4C1 is a cAMP uptake transporter for inhibiting lipogenesis and a therapeutic target for MASLD.

Hepatocyte SLCO4C1 is a cAMP uptake transporter for inhibiting lipogenesis and a therapeutic target for MASLD.

Journal: Nature communications
Published: June 20, 2025

FTO-dependent m6A methylation mediates gestational diabetes mellitus-induced offspring cardiac senescent hypertrophy and dysfunction.

FTO-dependent m6A methylation mediates gestational diabetes mellitus-induced offspring cardiac senescent hypertrophy and dysfunction.

Journal: iScience
Published: June 11, 2025

Identification of RUVBL2 as a novel biomarker to predict the prognosis and drug sensitivity in multiple myeloma based on ferroptosis genes.

Identification of RUVBL2 as a novel biomarker to predict the prognosis and drug sensitivity in multiple myeloma based on ferroptosis genes.

Journal: Hematology (Amsterdam, Netherlands)
Published: February 22, 2025

Exosomal tRF-1003 induces angiogenesis via regulating the HIF1α/VEGF signaling in multiple myeloma.

Exosomal tRF-1003 induces angiogenesis via regulating the HIF1α/VEGF signaling in multiple myeloma.

Journal: International immunopharmacology
Published: September 24, 2024

N6-methyladenosine-modified circ_0000337 sustains bortezomib resistance in multiple myeloma by regulating DNA repair.

N6-methyladenosine-modified circ_0000337 sustains bortezomib resistance in multiple myeloma by regulating DNA repair.

Journal: Frontiers in cell and developmental biology
Published: February 07, 2024

Activated platelet-derived exosomal LRG1 promotes multiple myeloma cell growth.

Activated platelet-derived exosomal LRG1 promotes multiple myeloma cell growth.

Journal: Oncogenesis
Published: October 12, 2023

STZ-induced gestational diabetes exposure alters PTEN/AKT/mTOR-mediated autophagy signaling pathway leading to increase the risk of neonatal hypoxic-ischemic encephalopathy.

STZ-induced gestational diabetes exposure alters PTEN/AKT/mTOR-mediated autophagy signaling pathway leading to increase the risk of neonatal hypoxic-ischemic encephalopathy.

Journal: Reproductive toxicology (Elmsford, N.Y.)
Published: August 10, 2023

CD38-targeted and erythrocyte membrane camouflaged nanodrug delivery system for photothermal and chemotherapy in multiple myeloma.

CD38-targeted and erythrocyte membrane camouflaged nanodrug delivery system for photothermal and chemotherapy in multiple myeloma.

Journal: International journal of pharmaceutics
Published: March 11, 2023

Evodiamine Selectively Inhibits Multiple Myeloma Cell Growth by Triggering Activation of Intrinsic Apoptosis Pathway.

Evodiamine Selectively Inhibits Multiple Myeloma Cell Growth by Triggering Activation of Intrinsic Apoptosis Pathway.

Journal: OncoTargets and therapy
Published: October 23, 2019

hsa_circ_0007841: A Novel Potential Biomarker and Drug Resistance for Multiple Myeloma.

hsa_circ_0007841: A Novel Potential Biomarker and Drug Resistance for Multiple Myeloma.

Journal: Frontiers in oncology
Published: June 02, 2019

Bortezomib-inducible long non-coding RNA myocardial infarction associated transcript is an oncogene in multiple myeloma that suppresses miR-29b.

Bortezomib-inducible long non-coding RNA myocardial infarction associated transcript is an oncogene in multiple myeloma that suppresses miR-29b.

Journal: Cell death & disease
Published: January 31, 2019
Showing 1-12 of 13

Last Updated: 09/26/2026